Case report: Pembrolizumab as an alternative to atezolizumab following a severe infusion reaction

Case report: Pembrolizumab as an alternative to atezolizumab following a severe infusion reaction

The emergence of immune-checkpoint inhibitors (ICIs) has revolutionized the field of oncology, providing promising results in various malignancies. However, ICIs can sometimes lead to severe injection reactions, requiring alternative treatment options. In this case report, we introduce a case of a s...

Full description

Bibliographic Details
Main Authors:	Seung Hyuk Lee, Hyeon Jong Kim, Hyun Jin Bang, Su Ji Park, Ji Eun Yu, Seung Woo Jeong, Woo Kyun Bae
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Series:	Frontiers in Oncology
Subjects:	immune-checkpoint inhibitors (ICIs) atezolizumab pembrolizumab infusion reaction hypersensitivity immune-related adverse drug reactions (ADRs)
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1273043/full

Similar Items

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
by: Muhammad Khan, et al.
Published: (2023-03-01)

Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature
by: Dongfeng Feng, et al.
Published: (2021-05-01)

Recommencement of atezolizumab with associated pulmonary sarcoid‐like reaction
by: Khai Tam, et al.
Published: (2024-05-01)

A case of sialadenitis observed as an irAE of atezolizumab: A case report
by: Kosumi Kumagai, et al.
Published: (2024-01-01)

Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis
by: Shengfa Lin, et al.
Published: (2024-12-01)

Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review
by: Nabil E. Omar, et al.
Published: (2020-10-01)

Infusion-Related Reactions Subsequent to Avelumab, Durvalumab, and Atezolizumab Administration: A Retrospective Observational Study
by: Keiko Hata, et al.
Published: (2024-02-01)

Clinical course and management of insidious adrenal crisis manifested initially as hyperpyrexia secondary to pembrolizumab: Case reports and literature review
by: Dandan Geng, et al.
Published: (2022-08-01)

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021-05-01)

Atezolizumab-Induced Ulcerative Colitis in Patient with Hepatocellular Carcinoma: Case Report and Literature Review
by: Hyuk Kim, et al.
Published: (2024-08-01)

Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
by: Zili Hu, et al.
Published: (2024-11-01)

A case of urticarial vasculitis associated with atezolizumab
by: Jade N. Young, BS, et al.
Published: (2024-01-01)

Immune Checkpoint Inhibitor-Induced Gastroduodenitis: Recurrence after Rechallenge with Pembrolizumab
by: Catarina O’Neill, et al.
Published: (2021-04-01)

The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience
by: Fateen Ata, et al.
Published: (2024-12-01)

Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
by: Alessandro Rizzo, et al.
Published: (2022-04-01)

Infusion-Related Reactions Induced by Cadonilimab (PD-1/CTLA-4 Bispecific Antibody): Seven Case Reports
by: Weiting Liang, et al.
Published: (2024-02-01)

Pembrolizumab on pre-existing inclusion body myositis: a case report
by: Naohiro Uchio, et al.
Published: (2020-09-01)

The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With Atezolizumab
by: Katherine E.R. Smith, MD, et al.
Published: (2023-12-01)

Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma
by: Takashi Tanaka, et al.
Published: (2022-07-01)

Unusual gingival presentation following treatment with pembrolizumab
by: Annu Singh, et al.
Published: (2024-03-01)

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)
by: M. Yu. Fedyanin, et al.
Published: (2023-06-01)

Atezolizumab‐related sclerosing cholangitis with multiple liver abscesses in a patient with lung squamous cell carcinoma: A case report
by: Daisuke Jingu, et al.
Published: (2024-03-01)

Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data
by: Connor Frey, et al.
Published: (2024-07-01)

Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis
by: Hazem E. El-Osta, et al.
Published: (2019-12-01)

Atezolizumab-induced encephalitis with subdural hemorrhage and subarachnoid hemorrhage in a patient with hepatocellular carcinoma
by: Ko-Han Chao, et al.
Published: (2023-11-01)

Pembrolizumab-induced asthma exacerbation with hypereosinophilia and elevated interleukin-5 in endometrial cancer: A case report
by: Tomoya Harada, et al.
Published: (2024-01-01)

Pembrolizumab-induced Stevens-Johnson syndrome-like reaction: An atypical clinical presentation
by: Arjun Mahajan, BS, MS, et al.
Published: (2024-12-01)

Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines
by: Saralinh Trinh, et al.
Published: (2019-01-01)

A case of severe acute hemorrhagic duodenitis after administration of immune checkpoint inhibitor
by: Keita Saito, et al.
Published: (2022-04-01)

Allergic bronchopulmonary mycosis induced by pembrolizumab for bladder cancer: A case report
by: Hiroki Iida, et al.
Published: (2025-01-01)

Eosinophilic fasciitis as an immune-related adverse event of Pembrolizumab in Hodgkin’s lymphoma: a case report
by: Kamil Khan, et al.
Published: (2024-06-01)

Pembrolizumab-Induced Lichen Planus on the Scalp of a Patient with Non-Small-Cell Lung Carcinoma
by: Aya Yamashita, et al.
Published: (2021-10-01)

Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis
by: Mike Nguyen, et al.
Published: (2019-09-01)

Pembrolizumab-Related Side Effects: Acute Renal Failure and Severe Neurological Toxicity
by: Gabriele Fasano, et al.
Published: (2022-01-01)

A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer
by: Kyung Woo Kim, et al.
Published: (2021-06-01)

Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors—A Systematic Review of the Literature
by: Cristina-Florina Pîrlog, et al.
Published: (2022-12-01)

Severe gastritis due to pembrolizumab treatment in a lung cancer patient
by: Noriko Hayama, et al.
Published: (2020-10-01)

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data
by: Hideki Terai, MD, et al.
Published: (2022-11-01)

Very Delayed Acute Hepatitis after Pembrolizumab Therapy for Advanced Malignancy: How Long Should We Watch?
by: Timothy Phan, et al.
Published: (2021-02-01)

Remitting seronegative symmetrical synovitis with pitting edema syndrome induced by pembrolizumab in patient with urothelial carcinoma
by: Akihiro Yoshimura, et al.
Published: (2022-07-01)